Pharma: Other News To Note
Tuesday, March 27, 2012
• Teva Pharmaceuticals Industries Ltd., of Jerusalem, said the FDA approved Qnasl, a dry nasal aerosol corticosteroid, for treating seasonal nasal and year-round nasal allergy symptoms in adults and adolescents 12 years and older. The product is expected to be available next month.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.